Study #2023-1022
A phase 1 trial evaluating the safety, tolerability, PK, and efficacy of QTX3034 in patients with solid tumors with KRAS (G12D) mutation
MD Anderson Study Status
Enrolling
Treatment Agent
QTX3034, Combination Product: Cetuximab
Description
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumors
Study phase:
Phase I
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-794-1615
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.